| Drug Name: | Levacetylmethadol (1477-40-3) |
|---|---|
| PubChem ID: | 15130 |
| SMILES: | CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C |
| InchiKey: | XBMIVRRWGCYBTQ-AVRDEDQJSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 353.506 |
| LogP | : | 4.6546 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 3 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 29.54 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Selegiline (14611-51-9) | Cardiac Arrhythmias | Antagonistic | Prolong the QT interval | The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Arrhythmias | Potassium voltage-gated channel subfamily H member 2 (Q12809) | Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category
| Toxicity | Source |
|---|